Derek Crouch, DO
Family Medicine · Henderson, NVNPI 1609160019
Payments from drug & device makers
Across 199 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$461
- Boehringer Ingelheim$375
- Novo Nordisk$339
- Astellas Pharma US Inc$295
- Lilly USA, LLC$227
- Novartis$225
- plus $2K from 31 others
What the payments were for
- Food & beverage$3,37897%
- Education$943%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 23 | $461 |
| Boehringer Ingelheim | 22 | $375 |
| Novo Nordisk | 22 | $339 |
| Astellas Pharma US Inc | 11 | $295 |
| Lilly USA, LLC | 17 | $227 |
| Novartis | 11 | $225 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $167 |
| GSK | 10 | $163 |
| Pfizer | 8 | $137 |
| Johnson & Johnson | 8 | $123 |
| Amgen | 5 | $85 |
| AstraZeneca | 5 | $80 |
| Abbott | 3 | $76 |
| Idorsia Pharmaceuticals US Inc | 4 | $61 |
| Amarin Pharma, Inc. | 4 | $61 |
| Esperion Therapeutics, Inc. | 3 | $57 |
| E.r. Squibb & Sons, L.L.C. | 3 | $57 |
| Bayer | 3 | $47 |
| Dexcom, Inc. | 2 | $42 |
| Hologic Sales And Service, LLC | 2 | $35 |
| Lundbeck LLC | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| Exact Sciences | 2 | $29 |
| Vanda Pharmaceuticals Inc. | 2 | $26 |
| Gilead | 1 | $25 |
| Boston Scientific | 1 | $24 |
| Bard Peripheral Vascular, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $19 |
| Halozyme Inc | 1 | $18 |
| Lucid Diagnostics Inc. | 1 | $18 |
| Bioventus LLC | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Braintree Laboratories, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$3,472 in reported general payments places this provider in the 85th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 158 | $150,264 |
| JardianceEmpagliflozin | 82 | $82,399 |
| OzempicSemaglutide | 41 | $42,212 |
| FarxigaDapagliflozin Propanediol | 23 | $36,695 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $31,066 |
| MounjaroTirzepatide | 24 | $29,985 |
| XareltoRivaroxaban | 36 | $25,914 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $16,555 |
| RybelsusSemaglutide | 17 | $15,815 |
| TrulicityDulaglutide | 13 | $12,241 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $11,822 |
| EntrestoSacubitril/Valsartan | 12 | $7,932 |
| MyrbetriqMirabegron | 17 | $7,650 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $7,327 |
| PremarinEstrogens, Conjugated | 19 | $7,084 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $137 | $157,348177 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $375 | $87,97493 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $80 | $67,76147 claims |
| Novo NordiskOzempic, Rybelsus | $339 | $58,02658 claims |
| Lilly USA, LLCMounjaro, Trulicity | $227 | $42,22537 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $163 | $30,58439 claims |
| Johnson & JohnsonXarelto | $123 | $25,91436 claims |
| NovartisEntresto | $225 | $7,93212 claims |
| Astellas Pharma US IncMyrbetriq | $295 | $7,65017 claims |
| AbbVieLinzess | $461 | $6,10811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 902 family medicine providers in Nevada.
Other family medicine in Henderson
- Rita ChuangHenderson$476K
- Vincent MirkilHenderson$82K
- Ibrahim FakhouriHenderson$51K
- Badi EghterafiHenderson$38K
- Gautham ReddyHenderson$17K
- Yuan-Chung ChenHenderson$13K
- Travis HailstoneHenderson$8K
- Rogelio MachucaLas Vegas$3.3M
- Maxine InghamLas Vegas$2.9M
- Elliot ShinLas Vegas$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.